$279,484.85 ownership Payment -- Gilead Sciences to Dr. Gregory Evans
Gilead Sciences reports substantial ownership interest payment to Ohio-based Infectious Disease specialist
This page provides a detailed analysis of a $279,484.85 ownership payment from Gilead Sciences to Dr. Gregory Evans. Data is from the CMS Open Payments (Sunshine Act) database.
Payment Details
| Field | Value |
|---|---|
| Amount | $279,484.85 |
| Payment Type | ownership |
| Payment Nature | Ownership or Investment Interest |
| Pharmaceutical Company | Gilead Sciences |
| Physician | Dr. Gregory Evans |
| NPI Number | 1457310631 |
| Physician Specialty | Infectious Disease |
| Location | Columbus, OH |
| Date of Payment | 2025-10-14 |
| Conflict Assessment | High -- Significant |
AI-Powered Analysis of This Payment
The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.
Gilead Sciences made a $279.5K ownership payment to Gregory Evans, a Infectious Disease specialist in Columbus, OH. Gilead Sciences reported a significant ownership interest payment of $279,484.85 to Dr. Gregory Evans, an Infectious Disease specialist in Ohio. This payment, categorized as 'Ownership or Investment Interest', occurred on October 14, 2025. The substantial amount suggests a potentially deep financial tie between the pharmaceutical company and the physician.
Patient Guidance: What This Payment Means for You
Patients should be aware that their physician may have financial interests in pharmaceutical companies, which could potentially influence treatment decisions. It is advisable to discuss any concerns about potential conflicts of interest with your healthcare provider. Always discuss your treatment options with your healthcare provider and ask about alternatives.
Payment Context: Is This Amount Normal?
Ownership or investment interest payments can vary widely, but a payment of this magnitude to an individual physician in Infectious Disease warrants attention when compared to typical consulting or speaking fees.
Regulatory Context: Sunshine Act Requirements
This transaction is subject to disclosure under the Physician Payments Sunshine Act (part of the Affordable Care Act), requiring transparency regarding financial relationships between drug manufacturers and physicians.
Related Topics
This payment is related to the following healthcare transparency topics:
- ownership-interest
- gilead-sciences
- infectious-disease
- physician-payment
- cms-open-payments
- investment-disclosure
Understanding ownership Payments
Ownership and investment interest payments represent dividends, returns, or other financial benefits from physician ownership stakes in pharmaceutical or medical device companies. These relationships represent the most direct form of financial interest and are subject to the strictest reporting requirements under the Sunshine Act.
Frequently Asked Questions About This Payment
What was this $279.5K payment for?
This was a ownership payment of $279.5K from Gilead Sciences to Gregory Evans, categorized as "Ownership or Investment Interest". The payment was reported under the Sunshine Act (CMS Open Payments).
Does Gregory Evans accept pharmaceutical money?
Yes, Gregory Evans received this $279.5K payment from Gilead Sciences. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Gregory Evans's full payment history on the CMS Open Payments database or on this site.
Is it legal for doctors to accept pharma payments?
Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.
Should I be concerned about this ownership payment?
A ownership payment of $279.5K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.
How do I talk to my doctor about pharma relationships?
You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.
What types of pharma payments are most concerning?
Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.
Does pharma money affect what my doctor prescribes?
Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.
How does this compare to other doctors in Infectious Disease?
To compare this payment against Infectious Disease averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Infectious Disease physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.
What does this payment reveal about Gregory Evans's relationship with Gilead Sciences?
The payment amount of $279,484.85 is notably high for an ownership interest. This $279.5K ownership payment is part of the transparency data reported under the Sunshine Act.
Is this payment amount typical for Infectious Disease?
The payment date is in the future (2025), which may indicate a planned or ongoing arrangement.
What should patients do after learning about this payment?
Patients should be aware that their physician may have financial interests in pharmaceutical companies, which could potentially influence treatment decisions. It is advisable to discuss any concerns about potential conflicts of interest with your healthcare provider.
What else should I know about this ownership payment?
Dr. Evans' specialty is Infectious Disease, a field where pharmaceutical companies often have significant product lines.
Related Reports
Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.